Compound Guides/Thymosin Alpha-1

Thymosin Alpha-1

Acetylated 28-Amino Acid Immunomodulatory Thymic Peptide

Updated November 2026·9 min read

Quick Facts

Full Name
Thymosin Alpha-1 (Thymalfasin / Zadaxin)
Structure Type
Linear peptide, N-terminally acetylated
Molecular Weight
3108.28 Da
Molecular Formula
C₁₂₉H₂₁₅N₃₃O₅₅
CAS Number
62304-98-7
Sequence (28 aa)
Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH
Origin
Synthetic; originally isolated from calf thymus tissue (thymosin fraction 5) in 1972
FDA Status
Not FDA-approved; 503A compounding eligibility restored (Feb 2026)
Human Clinical Data
30+ clinical trials; 11,000+ subjects across hepatitis, sepsis, and oncology indications
International Approvals
Marketed as Zadaxin in 35+ countries for chronic hepatitis B

1. What Is Thymosin Alpha-1

Thymosin Alpha-1 (Tα1), also known by its international nonproprietary name thymalfasin and the brand name Zadaxin, is a synthetic 28-amino acid peptide that corresponds to a naturally occurring thymic hormone. It was first isolated from calf thymus tissue by Allan Goldstein and colleagues at the University of Texas Medical Branch in 1972, as a component of thymosin fraction 5 — a partially purified extract from the thymus gland that was being investigated for its immunological activity.

The peptide's sequence — Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn — is N-terminally acetylated with a free C-terminal acid. It contains no cysteine or methionine residues, meaning there are no disulfide bonds and no sulfur-containing side chains. At 28 residues with a molecular weight of 3108.28 Da, it falls into the mid-size range for synthetic peptides.

Thymalfasin is the most clinically studied of the thymosin peptide family. It is approved in over 35 countries — primarily in Asia, Latin America, and parts of Europe — for the treatment of chronic hepatitis B, and has been investigated as an immune adjuvant in hepatitis C, sepsis, cancer immunotherapy, and vaccine enhancement. In the United States, thymosin alpha-1 has never received FDA approval for any indication. Its regulatory history in the U.S. has involved placement on and removal from the FDA's Category 2 bulk drug substances list, and as of February 2026, it is eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. This status allows preparation by compounding pharmacies under a physician's prescription but does not constitute FDA approval.

2. Mechanism of Action

Thymosin Alpha-1 is classified as an immunomodulator that acts primarily through innate immune signaling pathways. Its mechanism involves activation of dendritic cells through Toll-like receptor (TLR) signaling, with downstream effects on both innate and adaptive immune responses.

Toll-Like Receptor Signaling (TLR9 and TLR2)

The most consistently documented mechanism of Tα1 is activation of Toll-like receptor 9 (TLR9), expressed on dendritic cells and B cells. TLR9 activation drives type I interferon production and promotes a Th1-biased immune response. Multiple sources also report engagement of TLR2, which recognizes bacterial lipoproteins and contributes to inflammatory cytokine production. Through these receptors, Tα1 upregulates antigen presentation by dendritic cells and enhances the bridge between innate pathogen detection and adaptive immune activation.

Th1/Th2 Balance and T-Cell Maturation

Tα1 promotes differentiation of T helper cells toward a Th1 phenotype, which favors cell-mediated immunity over the humoral Th2 response. This shift is relevant to its investigation in chronic viral infections, where Th1-mediated cytotoxic T-cell activity is important for viral clearance. The peptide also promotes maturation of T lymphocytes from progenitor cells, restoring T-cell function in immunocompromised states — a mechanism consistent with its origin as a thymic hormone.

Natural Killer Cell Activation

Studies report that Tα1 enhances the cytotoxic activity of natural killer (NK) cells, which play a central role in innate defense against virus-infected and neoplastic cells. This effect, combined with increased interferon production, is part of the rationale for investigating Tα1 as an adjunct in cancer immunotherapy and as a vaccine enhancer.

IDO-Mediated Regulatory T-Cell Generation

Tα1 has been described as a bidirectional immunomodulator — it can stimulate immune activation while also promoting immune tolerance through indoleamine 2,3-dioxygenase (IDO)-mediated generation of regulatory T cells (Tregs). This dual action distinguishes it from purely stimulatory immune agents and is relevant to its investigation in conditions such as sepsis, where both immune activation and immune regulation are disrupted.

Pharmacokinetic data indicates a peak serum concentration 1 to 2 hours after subcutaneous injection, with a terminal half-life under 3 hours. However, downstream immunological effects — including changes in cytokine profiles and immune cell activity — are reported to persist for days beyond the peptide's elimination from circulation.

3. Clinical Evidence

Thymosin Alpha-1 has a substantial clinical trial history spanning hepatitis B, hepatitis C, sepsis, cancer adjunct therapy, and vaccine enhancement. More than 30 clinical trials have enrolled over 11,000 subjects. Post-marketing surveillance data from international use covers approximately 600,000 treated patients. However, the evidence base is mixed — early promising signals in some indications have not been consistently confirmed in larger, more rigorous trials.

Chronic Hepatitis B — the basis for international approvals. A randomized study of 98 patients with chronic hepatitis B found that a 26-week course of thymalfasin (1.6 mg subcutaneously twice weekly) produced complete virological response in 40.6% of treated patients versus 9.4% of untreated controls (p = 0.004). A 2001 meta-analysis described delayed virological responses that became clearest around 12 months after treatment ended — suggesting a sustained immunological effect rather than direct antiviral activity. These results formed the basis for Zadaxin's approval in over 35 countries. However, a 2026 Cochrane systematic review (PMID 42713852) evaluating 10 randomized controlled trials in chronic hepatitis B rated the overall evidence as"very low certainty" and could not confirm benefit on mortality or liver outcomes.
Sepsis — early promise not confirmed in Phase 3. A 2013 multicenter RCT (Wu et al., PMID 24206691) of 361 ICU patients with severe sepsis reported 28-day mortality of 26.0% in the treatment group versus 35.0% in the control group (p = 0.062) — a borderline result that did not reach statistical significance. The subsequent TESTS trial (BMJ 2025, PMID 39814420), a double-blind Phase 3 study enrolling 1,106 adults with sepsis across 22 centers in China, found 28-day mortality of 23.4% with thymalfasin versus 24.1% with placebo (corrected HR 0.97, 95% CI 0.76–1.24, p = 0.93). This definitive Phase 3 trial found no mortality benefit.
COVID-19 — mixed and inconclusive results. Multiple trials investigated Tα1 for COVID-19 (including NCT04428008 for renal dialysis patients and NCT04487444 for infected patients). A retrospective study of 76 severe COVID-19 patients (Liu et al., Clin Infect Dis 2020, PMID 32442287) reported lower mortality with treatment. However, a larger propensity-matched multicenter study in critically ill COVID-19 patients (PMID 33208294) found no mortality benefit. The results remain inconclusive.
Cancer adjunct therapy and vaccine enhancement. Tα1 has been studied as an adjunct to chemotherapy in melanoma and other cancers, and as a vaccine enhancer in elderly and immunocompromised populations. A 2009 Phase 2 melanoma trial and various hepatitis C combination studies have been published, but no indication has progressed to Phase 3 approval in the United States or Europe.

Regulatory Status

  • Not FDA-approved for any indication. SciClone Pharmaceuticals conducted U.S. Phase 3 trials in hepatitis C and melanoma but never filed a New Drug Application (NDA).
  • Approved internationally as Zadaxin in more than 35 countries for chronic hepatitis B, including China (1996) and Italy (1996). The standard approved regimen is 1.6 mg subcutaneously twice weekly for 26 weeks.
  • U.S. compounding history: FDA placed Tα1 on the Category 2 bulks list in 2023, halting 503A compounding. The nomination was withdrawn in September 2024 and the compound was removed from Category 2. In February 2026, HHS announced that Tα1 was among the peptides moved back to Category 1, restoring eligibility for 503A compounding under a physician's prescription. This is not FDA approval and does not imply an FDA safety or efficacy determination.
  • Orphan drug designation was granted by the FDA for hepatitis B in 1991.
  • Not WADA-prohibited. Unlike several other peptides, thymosin alpha-1 does not appear on the World Anti-Doping Agency's Prohibited List.

4. What to Look for in a COA

When evaluating a Certificate of Analysis for a Thymosin Alpha-1 product, confirm the following:

Identity confirmation via mass spectrometry — the intact mass should appear at approximately 3108.28 Da. ESI-MS will produce multiply charged ions (e.g., [M+3H]³⁺ at m/z ~1037, [M+4H]⁴⁺ at m/z ~778) that deconvolute to the parent mass. MALDI-TOF produces a singly charged [M+H]⁺ ion near 3109 Da

Verification of N-terminal acetylation — the acetyl group adds 42 Da to the mass. The non-acetylated (des-acetyl) form at approximately 3066 Da is a known synthesis byproduct. Its presence indicates incomplete acetylation during manufacturing

HPLC purity of 98% or higher from a named, independent third-party lab — measured by reversed-phase HPLC with UV detection at 214 nm (amide bond, universal) and optionally at 220 nm. Tα1 lacks tryptophan and tyrosine, so 280 nm absorbance is negligible and should not be used as the primary detection wavelength

Absence of des-acetyl thymosin alpha-1 — this impurity co-elutes closely with the target on some HPLC methods. A well-resolved method should show a clear separation between the two species, and any des-acetyl peak should be below 1–2% of total area

Peptide content (net peptide content after accounting for water, counterions, and residual salts) — typical acetate-salt preparations contain counterion and water content that reduces net peptide to 70–88% of gross weight. A labeled 5 mg vial may contain approximately 3.5–4.4 mg of active peptide

Water content by Karl Fischer titration and counterion identification (TFA or acetate salt form)

Endotoxin and sterility testing for any injectable preparation — with a batch or lot number matching the product received

A verifiable lab reference number from an independent, named testing laboratory — not a manufacturer’s in-house report alone

Red flags on a Thymosin Alpha-1 COA: missing mass spectrometry data (HPLC alone cannot confirm the 28-residue sequence or the critical N-terminal acetylation), purity below 95%, detection of des-acetyl Tα1 above 2% without disclosure, reporting only 280 nm UV detection (inappropriate for this peptide), absence of endotoxin results on injectable products, or missing net peptide content data.

For a full walkthrough of evaluating a COA, see our guide to reading a peptide COA.

5. Testing Considerations

Thymosin Alpha-1 presents specific analytical challenges due to its 28-residue length (placing it at the upper boundary of routine solid-phase peptide synthesis), its N-terminal acetylation requirement, and the high proportion of acidic residues in its sequence (seven glutamic acid and three aspartic acid residues out of 28 total).

Analytical Methods

The standard analytical approach uses reversed-phase HPLC with UV detection for purity assessment, combined with mass spectrometry for identity confirmation. UV detection is performed at 214–220 nm (amide bond absorbance). Unlike peptides containing tyrosine or tryptophan, Tα1 has negligible absorbance at 280 nm because its sequence contains no aromatic amino acids. For mass spectrometry, electrospray ionization (ESI-MS) produces multiply charged ions — the +3 and +4 charge states are typically most prominent for a peptide of this mass. MALDI-TOF is also effective and produces a dominant singly charged [M+H]⁺ ion at approximately 3109 Da.

N-Terminal Acetylation Verification

The N-terminal acetyl group is a defining structural feature of thymosin alpha-1. The natural peptide is acetylated in vivo, and the synthetic form must reproduce this modification. Des-acetyl thymosin alpha-1 (lacking the acetyl group) has a mass approximately 42 Da lower (~3066 Da) and represents a common synthesis impurity when the acetylation step is incomplete. Mass spectrometry is the primary method for confirming the presence of the acetyl group. Edman degradation (N-terminal sequencing) will show a blocked N-terminus for the correctly acetylated product, while the des-acetyl form will yield serine as the first residue.

Common Impurities

Synthesis-related impurities in Tα1 include truncated sequences (missing one or more residues), deletion peptides (internal residue omissions), and des-acetyl product. The high density of acidic residues (Asp and Glu) makes this peptide susceptible to aspartimide formation during synthesis — a side reaction at aspartic acid residues that produces β-aspartyl isomers and can reduce yield and purity. Deamidation of asparagine (the C-terminal residue) to aspartic acid is a common degradation pathway that adds approximately 1 Da to the mass. Racemization at individual residues produces diastereomeric impurities that may appear as shoulders on the main HPLC peak. Residual trifluoroacetic acid (TFA) from HPLC purification is another common contaminant in research-grade products.

Stability and Storage

As a lyophilized powder, Tα1 should be stored at -20°C in sealed, desiccated containers protected from light. The vial should reach room temperature before opening to prevent moisture condensation. The absence of cysteine and methionine residues means Tα1 is not susceptible to disulfide scrambling or methionine oxidation — two common degradation pathways in other peptides. However, the C-terminal asparagine is prone to deamidation, particularly at neutral to alkaline pH, and the multiple aspartic acid residues can undergo isomerization. Once reconstituted, solutions should be stored at 2–8°C for short-term use or aliquoted and frozen to avoid repeated freeze-thaw cycles.

Synthesis Complexity

At 28 residues, Tα1 is near the upper limit of what standard Fmoc solid-phase peptide synthesis handles routinely. Longer peptides have lower per-step coupling efficiency and accumulate more deletion and truncation impurities. The consecutive glutamic acid residues (positions 22–23 and 24–25) and the Lys-Lys motif (positions 19–20) can present aggregation and difficult-coupling challenges during chain assembly. These synthesis difficulties mean that manufacturer quality varies more for 28-residue peptides than for shorter sequences, making independent third-party testing particularly important.

Net Peptide Content

Tα1 is commonly supplied as an acetate or TFA salt. When accounting for water content (typically 3–7% by Karl Fischer) and counterions (TFA or acetate, potentially 10–15% by weight), net peptide content of lyophilized powders typically ranges from 70–88%. A properly detailed COA should report both gross weight and net peptide content, with the analytical method (nitrogen analysis or amino acid analysis) used to determine peptide content clearly stated. The high proportion of acidic residues means Tα1 binds more counterion mass per peptide mass than a neutral or basic peptide of similar length.

Summary

Thymosin Alpha-1 is a synthetic 28-amino acid acetylated peptide that acts as an immunomodulator through TLR9 and TLR2 signaling on dendritic cells. It is approved in over 35 countries as Zadaxin for chronic hepatitis B but has never received FDA approval, despite being the subject of more than 30 clinical trials. The largest controlled trial — the TESTS Phase 3 sepsis study — found no mortality benefit. U.S. 503A compounding eligibility was restored in February 2026.

When evaluating a Tα1 product, prioritize third-party lab testing showing HPLC purity at or above 98%, mass spectrometric identity confirmation at approximately 3108 Da with verification of N-terminal acetylation, absence of des-acetyl impurity, net peptide content determination, and — for any injectable preparation — verified endotoxin and sterility testing from an independent laboratory.